Agenus Prophage vaccine Stage 2 research hailed in Neuro-Oncology journal Agenus Inc.

We are worked up about these outcomes and the enthusiasm of our co-workers, said Andrew Parsa, MD, PhD, corresponding writer of the study and seat of neurological surgery at Northwestern Memorial Medical center and the Michael J. We are also thinking about the ongoing NCI Alliance trial and the chance to not only advance a new therapy for individuals with GBM but to aid the advancement of innovative immunologic and imaging tools. .. Agenus’ Prophage vaccine Stage 2 research hailed in Neuro-Oncology journal Agenus Inc. , a biotechnology company developing novel disease fighting capability activating remedies for cancers and infectious illnesses, announced that Phase 2 results of Prophage G-200 vaccine in recurrent individuals with glioblastoma multiforme were hailed as 'thrilling' and a 'very promising therapy' in an editorial released in Neuro-Oncology, the leading journal of the Culture of Neuro-Oncology.Leg cellulitis created and was treated with cephalexin and topical gentamicin. The patient was discharged with a prescription for clindamycin but was readmitted in June 2012 because of worsening psychiatric symptoms and recurrent infections of the skin and soft cells. Cefepime and Vancomycin were administered for 8 days; blood cultures attained during this time period were sterile. The patient remained in the hospital to receive chemotherapy with gemcitabine, vinorelbine, and dexamethasone for mycosis fungoides . On 16 and 24 July, bloodstream cultures yielded MRSA isolates which were vunerable to vancomycin, linezolid, and clindamycin . Vancomycin was continued for 13 times . The fever diminished, and daptomycin was continued for yet another 4 weeks.